These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21050800)

  • 1. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Andes D; Diekema DJ; Espinel-Ingroff A; Sheehan D;
    Drug Resist Updat; 2010 Dec; 13(6):180-95. PubMed ID: 21050800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
    Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Susceptibility to fluconazole of clinical interest yeasts: new breakpoints].
    García-Agudo L; García-Martos P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):266-8. PubMed ID: 23303258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
    Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EUCAST technical note on Amphotericin B.
    Lass-Flörl C; Arendrup MC; Rodriguez-Tudela JL; Cuenca-Estrella M; Donnelly P; Hope W;
    Clin Microbiol Infect; 2011 Dec; 17(12):E27-9. PubMed ID: 22011310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EUCAST breakpoints for antifungals.
    Rodríguez-Tudela JL; Arendrup MC; Cuenca-Estrella M; Donnelly JP; Lass-Flörl C
    Drug News Perspect; 2010 Mar; 23(2):93-7. PubMed ID: 20369073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates.
    Claudino AL; Peixoto RF; Melhem MS; Szeszs MW; Lyon JP; Chavasco JK; Franco MC
    Pharmazie; 2008 Apr; 63(4):286-9. PubMed ID: 18468388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
    Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
    Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
    Espinel-Ingroff A; Arendrup MC; Pfaller MA; Bonfietti LX; Bustamante B; Canton E; Chryssanthou E; Cuenca-Estrella M; Dannaoui E; Fothergill A; Fuller J; Gaustad P; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Meis JF; Moore CB; Ostrosky-Zeichner L; Pelaez T; Pukinskas SR; St-Germain G; Szeszs MW; Turnidge J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5836-42. PubMed ID: 24018263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
    Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
    Espinel-Ingroff A; Cantón E
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
    Linares MJ; Charriel G; Solís F; Casal M
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
    Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
    J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.